颅咽管瘤免疫微环境的单细胞转录组学分析及PE_EGR2亚群生长信号通路研究
Single-Cell Transcriptomic Analysis of the Immune Microenvironment in Adamantinomatous Craniopharyngioma and Growth Signaling Pathways of the PE_EGR2 Subpopulation
DOI: 10.12677/acm.2026.1641367, PDF,   
作者: 余秋锦*:重庆医科大学附属第二医院超声科,重庆;吉 翔:重庆医科大学附属第二医院神经外科,重庆;尤君元#:重庆医科大学附属第二医院重症医学科,重庆
关键词: 颅咽管瘤单细胞转录组肿瘤免疫微环境细胞通讯EGFRFGF/FGFR干性Craniopharyngioma Single-Cell Transcriptomics Tumor Immune Microenvironment Cell Communication EGFR FGF/FGFR Stemness
摘要: 目的:系统解析成釉细胞型颅咽管瘤(Adamantinomatous Craniopharyngioma, ACP)肿瘤免疫微环境的细胞组成与功能状态,并重点探讨高干性肿瘤上皮亚群PE_EGR2的生长信号通路通讯网络,为ACP靶向治疗提供新的理论依据。方法:整合5个公开数据集共81,050个单细胞转录组数据,涵盖21例样本。采用Harmony算法进行批次效应校正,重建UMAP低维嵌入。通过Wilcoxon秩和检验鉴定免疫细胞标志基因,利用CytoTRACE 2深度学习框架评估肿瘤上皮细胞分化潜能,并以LIANA rank_aggregate共识方法推断细胞间配体–受体通讯。结果:共鉴定27种细胞类型,免疫细胞占44.1%,肿瘤上皮细胞占37.8%。髓系细胞(以M0样驻留巨噬细胞为主,占免疫细胞41.4%)构成免疫微环境的核心成分,呈现显著的M2样免疫抑制极化特征。T细胞亚群中检测到明显的耗竭信号(PDCD1HAVCR2TIGIT高表达)。CytoTRACE 2分析显示PE_EGR2亚群具有最高干性潜能(中位评分0.435)。细胞通讯分析识别出172对显著配体–受体互作,其中33对涉及生长通路,PE_EGR2通过GSTP1/ANXA1 → EGFR轴向其他肿瘤上皮亚群发送强烈的EGF信号,同时接收来自神经胶质细胞的FGF14 → FGFR2信号。结论:ACP肿瘤微环境呈现高度免疫抑制状态,PE_EGR2亚群兼具高干性和活跃的生长信号发送能力,是ACP肿瘤维持与扩张的潜在关键驱动亚群,EGFR抑制剂与FGFR抑制剂联合免疫检查点阻断可能是ACP综合治疗的潜在策略。
Abstract: Object: To systematically characterize the cellular composition and functional states of the tumor immune microenvironment (TME) in adamantinomatous craniopharyngioma (ACP), with a focus on elucidating the growth signaling communication network of the high-stemness tumor epithelial subpopulation PE_EGR2, thereby providing a theoretical basis for targeted therapy of ACP. Methods: Single-cell transcriptomic data from 81,050 cells across 21 samples were integrated from five public datasets. Batch effects were corrected using the Harmony algorithm, followed by UMAP dimensionality reduction. Wilcoxon rank-sum tests were applied to identify immune cell marker genes. The CytoTRACE 2 deep learning framework was used to assess the differentiation potential of tumor epithelial cells, and the LIANA rank_aggregate consensus method was employed to infer ligand-receptor-mediated intercellular communication. Results: A total of 27 cell types were identified, with immune cells comprising 44.1% and tumor epithelial cells 37.8% of all cells. Myeloid cells, predominantly M0-like resident macrophages (41.4% of immune cells), constituted the core of the immune microenvironment and exhibited prominent M2-like immunosuppressive polarization. T cell subpopulations displayed marked exhaustion signatures, characterized by high expression of PDCD1, HAVCR2, and TIGIT. CytoTRACE 2 analysis revealed that the PE_EGR2 subpopulation possessed the highest stemness potential (median score 0.435). Cell communication analysis identified 172 significant ligand-receptor interactions, of which 33 involved growth-related pathways. PE_EGR2 transmitted potent EGF signals to other tumor epithelial subpopulations via the GSTP1/ANXA1 → EGFR axis, while receiving FGF14 → FGFR2 signals from glial cells. Conclusion: The ACP tumor microenvironment is characterized by profound immunosuppression. The PE_EGR2 subpopulation combines high stemness with active growth signal transmission, representing a potential key driver of ACP maintenance and expansion. Combined targeting of EGFR/FGFR signaling with immune checkpoint blockade may constitute a promising therapeutic strategy for ACP.
文章引用:余秋锦, 吉翔, 尤君元. 颅咽管瘤免疫微环境的单细胞转录组学分析及PE_EGR2亚群生长信号通路研究[J]. 临床医学进展, 2026, 16(4): 1346-1358. https://doi.org/10.12677/acm.2026.1641367

参考文献

[1] Gonzalez-Meljem, J.M., Cao, L., Apps, J.R. and Martinez-Barbera, J.P. (2025) Decoding Craniopharyngioma: From Mechanisms to Therapy. Best Practice & Research Clinical Endocrinology & Metabolism, 39, Article ID: 102051. [Google Scholar] [CrossRef
[2] Apps, J.R., Carreno, G., Gonzalez-Meljem, J.M., Haston, S., Guiho, R., Cooper, J.E., et al. (2018) Tumour Compartment Transcriptomics Demonstrates the Activation of Inflammatory and Odontogenic Programmes in Human Adamantinomatous Craniopharyngioma and Identifies the MAPK/ERK Pathway as a Novel Therapeutic Target. Acta Neuropathologica, 135, 757-777. [Google Scholar] [CrossRef] [PubMed]
[3] An, W., Li, S., An, Y. and Lin, Z. (2025) Molecular Subtypes of Adamantinomatous Craniopharyngiomas. Neuro-Oncology, 27, 1180-1192. [Google Scholar] [CrossRef] [PubMed]
[4] Pires de Oliveira Neto, C., Nascimento, G.C., Damianse, S.d.S.P. and Faria, M.d.S. (2025) Recent Advances in Craniopharyngioma Pathophysiology and Emerging Therapeutic Approaches. Frontiers in Endocrinology, 16, Article ID: 1562942. [Google Scholar] [CrossRef] [PubMed]
[5] Apps, J.R., Gonzalez-Meljem, J.M., Guiho, R., Pickles, J.C., Prince, E., Schwalbe, E., et al. (2024) Recurrent Adamantinomatous Craniopharyngiomas Show MAPK Pathway Activation, Clonal Evolution and Rare Tp53-Loss-Mediated Malignant Progression. Acta Neuropathologica Communications, 12, Article No. 127. [Google Scholar] [CrossRef] [PubMed]
[6] Lin, D., Wang, Y., Zhou, Z., et al. (2019) Immune Microenvironment of Primary and Recurrent Craniopharyngiomas: A Study of the Differences and Clinical Significance. World Neurosurgery, 126, e1056-e1063.
[7] Gao, Q., Luo, J., Pan, J., Zhang, L., Song, D., Zhang, M., et al. (2022) Integrative Analyses Identify Hif-1α as a Potential Protective Role with Immune Cell Infiltration in Adamantinomatous Craniopharyngioma. Frontiers in Immunology, 13, Article ID: 949509. [Google Scholar] [CrossRef] [PubMed]
[8] Xu, C., Wu, J., Ye, J., Si, Y., Zhang, J., Wu, B., et al. (2024) Multiomics Integration-Based Immunological Characterizations of Adamantinomatous Craniopharyngioma in Relation to Keratinization. Cell Death & Disease, 15, Article No. 439. [Google Scholar] [CrossRef] [PubMed]
[9] Coy, S., Rashid, R., Lin, J., Du, Z., Donson, A.M., Hankinson, T.C., et al. (2018) Multiplexed Immunofluorescence Reveals Potential PD-1/PD-L1 Pathway Vulnerabilities in Craniopharyngioma. Neuro-Oncology, 20, 1101-1112. [Google Scholar] [CrossRef] [PubMed]
[10] Jiang, Y., Yang, J., Liang, R., Zan, X., Fan, R., Shan, B., et al. (2023) Single-Cell RNA Sequencing Highlights Intratumor Heterogeneity and Intercellular Network Featured in Adamantinomatous Craniopharyngioma. Science Advances, 9, eadc8933. [Google Scholar] [CrossRef] [PubMed]
[11] Matsuda, T., Kono, T., Taki, Y., Sakuma, I., Fujimoto, M., Hashimoto, N., et al. (2024) Deciphering Craniopharyngioma Subtypes: Single-Cell Analysis of Tumor Microenvironment and Immune Networks. iScience, 27, Article ID: 111068. [Google Scholar] [CrossRef] [PubMed]
[12] Zhang, B., Zhang, J., Li, Z., Sheng, H., Li, H., Lu, Y., et al. (2025) Interrogation of the Cellular Hierarchies Reveals Neoplastic Evolution and Therapeutic Vulnerability in Craniopharyngioma. Neuro-Oncology, 28, 191-205. [Google Scholar] [CrossRef
[13] Kang, M., Gulati, G.S., Brown, E.L., Qi, Z., Avagyan, S., Armenteros, J.J.A., et al. (2025) Improved Reconstruction of Single-Cell Developmental Potential with Cytotrace 2. Nature Methods, 22, 2258-2263. [Google Scholar] [CrossRef
[14] Gulati, G.S., Sikandar, S.S., Wesche, D.J., Manjunath, A., Bharadwaj, A., Berger, M.J., et al. (2020) Single-Cell Transcriptional Diversity Is a Hallmark of Developmental Potential. Science, 367, 405-411. [Google Scholar] [CrossRef] [PubMed]
[15] Dimitrov, D., Türei, D., Garrido-Rodriguez, M., Burmedi, P.L., Nagai, J.S., Boys, C., et al. (2022) Comparison of Methods and Resources for Cell-Cell Communication Inference from Single-Cell RNA-Seq Data. Nature Communications, 13, Article No. 3224. [Google Scholar] [CrossRef] [PubMed]
[16] Dimitrov, D., Schäfer, P.S.L., Farr, E., Rodriguez-Mier, P., Lobentanzer, S., Badia-i-Mompel, P., et al. (2024) LIANA+ Provides an All-in-One Framework for Cell-Cell Communication Inference. Nature Cell Biology, 26, 1613-1622. [Google Scholar] [CrossRef] [PubMed]
[17] Ji, S., Shi, Y. and Yin, B. (2024) Macrophage Barrier in the Tumor Microenvironment and Potential Clinical Applications. Cell Communication and Signaling, 22, Article No. 74. [Google Scholar] [CrossRef] [PubMed]
[18] Toledo, B., Zhu Chen, L., Paniagua-Sancho, M., Marchal, J.A., Perán, M. and Giovannetti, E. (2024) Deciphering the Performance of Macrophages in Tumour Microenvironment: A Call for Precision Immunotherapy. Journal of Hematology & Oncology, 17, Article No. 44. [Google Scholar] [CrossRef] [PubMed]
[19] Jhunjhunwala, S., Hammer, C. and Delamarre, L. (2021) Antigen Presentation in Cancer: Insights into Tumour Immunogenicity and Immune Evasion. Nature Reviews Cancer, 21, 298-312. [Google Scholar] [CrossRef] [PubMed]
[20] Dhatchinamoorthy, K., Colbert, J.D. and Rock, K.L. (2021) Cancer Immune Evasion through Loss of MHC Class I Antigen Presentation. Frontiers in Immunology, 12, Article ID: 636568. [Google Scholar] [CrossRef] [PubMed]
[21] Balasubramanian, A., John, T. and Asselin-Labat, M. (2022) Regulation of the Antigen Presentation Machinery in Cancer and Its Implication for Immune Surveillance. Biochemical Society Transactions, 50, 825-837. [Google Scholar] [CrossRef] [PubMed]
[22] Zhang, H., Li, S., Wang, D., Liu, S., Xiao, T., Gu, W., et al. (2024) Metabolic Reprogramming and Immune Evasion: The Interplay in the Tumor Microenvironment. Biomarker Research, 12, Article No. 96. [Google Scholar] [CrossRef] [PubMed]
[23] Tufail, M., Jiang, C. and Li, N. (2025) Immune Evasion in Cancer: Mechanisms and Cutting-Edge Therapeutic Approaches. Signal Transduction and Targeted Therapy, 10, Article No. 227. [Google Scholar] [CrossRef] [PubMed]
[24] Wang, R., Zhuang, J., Zhang, Q., Wu, W., Yu, X., Zhang, H., et al. (2025) Decoding the Metabolic Dialogue in the Tumor Microenvironment: From Immune Suppression to Precision Cancer Therapies. Experimental Hematology & Oncology, 14, Article No. 99. [Google Scholar] [CrossRef] [PubMed]
[25] Ma, G., Zhang, Z., Li, P., Zhang, Z., Zeng, M., Liang, Z., et al. (2022) Reprogramming of Glutamine Metabolism and Its Impact on Immune Response in the Tumor Microenvironment. Cell Communication and Signaling, 20, Article No. 114. [Google Scholar] [CrossRef] [PubMed]
[26] Prince, E.W., Apps, J.R., Jeang, J., Chee, K., Medlin, S., Jackson, E.M., et al. (2024) Unraveling the Complexity of the Senescence-Associated Secretory Phenotype in Adamantinomatous Craniopharyngioma Using Multimodal Machine Learning Analysis. Neuro-Oncology, 26, 1109-1123. [Google Scholar] [CrossRef] [PubMed]
[27] Guo, R., Wang, R., Zhang, W., Li, Y., Wang, Y., Wang, H., et al. (2025) Multifaceted Regulatory Mechanisms of the EGR Family in Tumours and Prospects for Therapeutic Applications (Review). International Journal of Molecular Medicine, 56, Article No. 113. [Google Scholar] [CrossRef] [PubMed]
[28] Pagin, M., Pernebrink, M., Giubbolini, S., Barone, C., Sambruni, G., Zhu, Y., et al. (2021) Sox2 Controls Neural Stem Cell Self-Renewal through a Fos-Centered Gene Regulatory Network. Stem Cells, 39, 1107-1119. [Google Scholar] [CrossRef] [PubMed]
[29] Regan, J.L., Schumacher, D., Staudte, S., Steffen, A., Lesche, R., Toedling, J., et al. (2022) Identification of a Neural Development Gene Expression Signature in Colon Cancer Stem Cells Reveals a Role for EGR2 in Tumorigenesis. iScience, 25, Article ID: 104498. [Google Scholar] [CrossRef] [PubMed]
[30] Buchou, C., Laud-Duval, K., van der Ent, W., Grossetête, S., Zaidi, S., Gentric, G., et al. (2022) Upregulation of the Mevalonate Pathway through EWSR1-FLI1/EGR2 Regulatory Axis Confers Ewing Cells Exquisite Sensitivity to Statins. Cancers, 14, Article No. 2327. [Google Scholar] [CrossRef] [PubMed]
[31] Talukdar, S., Emdad, L., Das, S.K., et al. (2020) EGFR: An Essential Receptor Tyrosine Kinase-Regulator of Cancer Stem Cells. Advances in Cancer Research, 147, 161-188.
[32] Uribe, M.L., Marrocco, I. and Yarden, Y. (2021) EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance. Cancers, 13, Article No. 2748. [Google Scholar] [CrossRef] [PubMed]
[33] Yang, J., Liao, D., Chen, C., Liu, Y., Chuang, T., Xiang, R., et al. (2013) Tumor-Associated Macrophages Regulate Murine Breast Cancer Stem Cells through a Novel Paracrine EGFR/Stat3/Sox-2 Signaling Pathway. Stem Cells, 31, 248-258. [Google Scholar] [CrossRef] [PubMed]
[34] Klimaschewski, L. and Claus, P. (2021) Fibroblast Growth Factor Signalling in the Diseased Nervous System. Molecular Neurobiology, 58, 3884-3902. [Google Scholar] [CrossRef] [PubMed]
[35] Ardizzone, A., Scuderi, S.A., Giuffrida, D., Colarossi, C., Puglisi, C., Campolo, M., et al. (2020) Role of Fibroblast Growth Factors Receptors (FGFRs) in Brain Tumors, Focus on Astrocytoma and Glioblastoma. Cancers, 12, Article No. 3825. [Google Scholar] [CrossRef] [PubMed]
[36] Babina, I.S. and Turner, N.C. (2017) Advances and Challenges in Targeting FGFR Signalling in Cancer. Nature Reviews Cancer, 17, 318-332. [Google Scholar] [CrossRef] [PubMed]
[37] Zhang, P., Yue, L., Leng, Q., Chang, C., Gan, C., Ye, T., et al. (2024) Targeting FGFR for Cancer Therapy. Journal of Hematology & Oncology, 17, Article No. 39. [Google Scholar] [CrossRef] [PubMed]